ClinicalTrials.gg
RecruitingNCT05866458ROSALIEUpdated Oct 13, 2026

Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy

An observational study in Breast Cancer, sponsored by Ontario Clinical Oncology Group (OCOG). Recruiting at 27 sites in 2 countries. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Ontario Clinical Oncology Group (OCOG) · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
352
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG) — 2 open to participants now, 4 under way, 2 of them phase 3. Breast Neoplasms · Ontario Clinical Oncology Group (OCOG).

Started
2024
the only one that year
Observational
4 of 24
1 open now
Registered
24th of 24
by date

Among the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG), this one is the only one that started in 2024, is one of 4 observational ones, and was the 24th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG) are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG), or all of them as a file.
02

Study summary

To de-escalate radiation therapy in women with breast cancer.

Read the detailed description

The study is a prospective, multi-center, single arm cohort study of omission of adjuvant whole breast radiation therapy (WBRT) following breast conserving surgery (BCS) in patients with a pathological complete response (pCR) following neoadjuvant chemotherapy (NAC). Eligible and consenting female patients with newly diagnosed T1-3 node negative breast cancer with no clinical evidence of distant metastatic disease, who have been treated with NAC, BCS and axillary staging surgery with final pathology demonstrating a pCR (ypT0N0) will be enrolled to the study and followed. The first analysis is planned when follow-up is a median of 5 years. Study participants will not receive adjuvant WBRT, the current standard of care.

The primary outcome is ipsilateral breast tumour recurrence (IBTR) at median 5-year follow-up. Study participants will be followed and assessed for local recurrence, regional recurrence, distant recurrence, DFS and OS. In addition, any additional breast cancer treatments received by the participant for the first recurrence event including repeat BCS, mastectomy, additional systemic therapy and radiation therapy (RT) will be documented. The planned sample size is 352 study participants.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Clinically node negative breast cancer
  • Ipsilateral breast tumour recurrence
  • Neoadjuvant chemotherapy
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Written informed consent will be obtained from all eligible patients who agree to participate. Until the patient has been completely informed of the study, has freely consented to take part in the study and has signed and dated an informed consent form that has received documented approval by an authorized Research Ethics Board (REB), no study related assessments, including those required for screening can be performed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patient with a new histological diagnosis of clinical T1-3 N0 breast cancer (any tumour sub-type).
  2. Negative lymph node involvement at initial presentation, documented by imaging (US or MRI), fine needle aspiration (FNA) or core needle .
  3. Treated with a minimum of 8 weeks NAC, with patients with Her2+ disease receiving targeted anti-Her2+ therapy.
  4. Marker clip placed in the tumour bed prior to or during chemotherapy when the tumour can still be identified.
  5. Treated by BCS with complete excision of the tumour bed and axillary staging surgery (either sentinel lymph node biopsy or axillary lymph node dissection).
  6. Final pathology demonstrating a pCR [defined as absence of residual invasive and in-situ breast cancer within the breast or lymph nodes (ypT0N0)].

Exclusion criteria

Exclusion Criteria:

  1. Age less than 50 years.
  2. Inflammatory breast cancer or breast cancer invading the skin or chest wall (T4 disease).
  3. Multicentric disease (i.e., breast cancer involving more than one quadrant in the same breast).
  4. Prior history of ipsilateral or contralateral in-situ or invasive breast cancer. Patients with a history of lobular carcinoma in-situ (LCIS) are ineligible.
  5. Synchronous contralateral in-situ or invasive breast cancer.
  6. BRCA (breast cancer gene) 1 or 2 genetic mutation carrier, or other genetic mutation present associated with increased risk of breast cancer.
  7. Other previous non-breast except adequately treated non-melanoma skin cancers, in situ cancers or other cancers curatively treated with no evidence of disease for ≥ 5 years.
  8. Inability to complete entire course of therapy (minimum of 8 weeks of treatment).
  9. Patients with HR+ (hormone receptor) disease who are not planned to have endocrine therapy initiated.
  10. Patients with Her2+ disease who have not received or are not planned to receive Her2 targeted therapy.
  11. (Eastern Cooperative Oncology Group) performance status > 3.
  12. Inability to provide .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
352 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single Arm Cohort

    The study population consists of women with newly diagnosed T1-3 node negative breast cancer with no clinical evidence of distant metastatic disease, that have been treated with NAC, BCS and axillary staging surgery with final pathology demonstrating a pCR (defined as absence of residual invasive and in situ breast cancer within the breast or lymph nodes).

06

What researchers measure

Primary outcomes

  1. Ipsilateral breast tumour recurrence (IBTR)

    defined as ipsilateral recurrence (invasive or insitu) in the ipsilateral breast or chest wall. Histological evidence of IBTR is required. All such events will be reviewed by a central adjudication committee.

    Time frame: 5 years

Secondary outcomes

  1. Mastectomy free interval

    defined as time from registration to undergoing ipsilateral mastectomy.

    Time frame: 5 years

  2. Relapse free interval (RFI)

    defined as time from registration to recurrence of invasive disease in the ipsilateral breast, regional nodes (axilla, supraclavicular, or internal mammary), distant areas beyond local or regional limits (distant recurrence), and death from breast cancer.

    Time frame: 5 years

  3. Disease free survival (DFS)

    defined as time from registration to in breast invasive tumour recurrence, regional invasive recurrence, distant recurrence, contralateral breast cancer, second primary non-breast cancers, death from breast cancer, and death from non-breast cancer.

    Time frame: 5 years

  4. Overall survival (OS)

    defined as time from registration to death from any cause.

    Time frame: 5 years

07

Study locations

27 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Oct 2031, 91 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 91 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2023
First posted
May 19, 2023
StartActual
Mar 12, 2024
Primary completionEst.
Oct 2031
CompletionEst.
Oct 2031
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Princess Alexandra Hospital · Woolloongabba, AustraliaContact person changed (no phone or email listed)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Princess Alexandra Hospital · Woolloongabba, AustraliaContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05866458
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Collaborators
Canadian Institutes of Health Research (CIHR), Hamilton Health Sciences Corporation
Responsible party
Sponsor
First posted
May 19, 2023
Start date
Mar 12, 2024
Primary completion
Oct 2031 (estimated)
Completion
Oct 2031 (estimated)
Last update
Oct 13, 2026

Study contacts

Adrianne Van Dam
Contact
avandam@mcmaster.ca
905-527-2299 ext. 42607
Elena Parvez, MD
principal investigator · Juravinski Cancer Centre
Thierry Muanza, MD
principal investigator · Jewish General Hospital
Mark Basik, MD
principal investigator · Jewish General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion